Audience Poll: Validation and Trust Are Biggests Barriers to Organ on Chip Adoption

Why It Matters

Without independent validation and regulatory alignment, organ-on-chip technologies risk stalled commercialization and limited uptake despite technical progress; NIH-backed coordination aims to reduce risk and accelerate adoption by building trust and clear pathways for use.

Summary

An audience poll found that 46% of respondents say validation and trust are the biggest barriers to broader organ-on-chip adoption, with regulatory acceptance cited by 25%, cost and scalability by about 19%, and workflow integration by 9%. Panelists said the result was expected, noting the field’s rapid technology development has outpaced confidence in data and real-world use cases. NIH has funded a program to support validation efforts by bringing together technology developers, end users and regulators to define standards and address specific questions. Organ-on-chip proponents argue coordinated validation and stakeholder engagement are essential to move from innovation to reliable, deployable tools.

Original Description

In a live audience poll, 46% of respondents cited validation and trust as the biggest barriers to broader organ on chip adoption. The result suggests the technology itself is no longer the main hurdle; instead, confidence in reproducibility, benchmarking, and fit for purpose use will determine how quickly these models are integrated into drug discovery decision making.

See more at https://www.drugdiscoveryonline.com/